Company Update (NASDAQ:EYES): Second Sight Medical Products Inc Announces Publication of Positive Results in 3-Year FLORA Study of the Argus II

Second Sight Medical Products Inc (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics to restore some useful vision to blind patients, today announced the publication of a positive 3-year FLORA study in the Australian journal Clinical And Experimental Optometry for the Argus® II Retinal Prosthesis System.

The Functional Low-Vision Observer Rated Assessment (FLORA), a multi-part instrument that was developed specifically for use in patients implanted with a retinal prosthesis who suffer from profound loss of vision or blindness, was used to assess the functional visual abilities of 26 blind patients and how they use the Argus II to complete a series of common activities of daily living. Before the development of the FLORA, there were no accepted, standardized assessments of functional vision or quality of life that could be used to assess the kind of vision that is restored by a retinal prosthesis. Common assessment tools of functional vision that are available such as the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) or the Massof Activity Inventory have only a few items that can be completed by those with ultra-low vision, with the majority of test items requiring higher levels of spatial vision (ability to read, recognize faces, identify colors).

Study subjects served as their own controls and completion of tasks were compared with the system “ON” versus “OFF”.

24 of 35 tasks (69%) showed a statistically significant improvement in outcome with the device “ON” versus “OFF” while only two tasks (6%) showed a decrease in outcome. Nine tasks (26%) showed no significant change.

“We are thrilled, yet not surprised, with the results of this study,” said Will McGuire, President and CEO of Second Sight. “Since the beginning, we have heard from the majority of individuals with the Argus II that our technology has changed their life and greatly enhanced their ability to perform tasks and activities of daily life. This study validates the positive feedback we’ve been receiving from our recipients all along.”

The Argus II is a device that induces visual perception in blind individuals with retinitis pigmentosa (RP) by providing electrical pulses to stimulate the retina’s remaining cells, resulting in a perception of light patterns in the brain. Patients learn to interpret these light patterns to enhance their daily lives and visual function in a sighted world.

Future enhancements to the Argus II currently being developed by the company will focus on external hardware improvements and software upgrades so that current Argus II users may have the opportunity to benefit from the continually advancing technology. (Original Source)

Shares of Second Sight Medical Products closed last Friday at $4.13. EYES has a 1-year high of $19.63 and a 1-year low of $3.40. The stock’s 50-day moving average is $4.66 and its 200-day moving average is $7.10.

Second Sight Medical Products Inc develops, manufactures and markets implantable prosthetic devices that can restore some functional vision to patients blinded by outer retinal degenerations, such as Retinitis Pigmentosa.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts